Integra Lifesciences Holdings Corp(IART) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:10 PM ET (Korea 9/12 05:10)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.09 | Insider Own | 14.46% | Shs Outstand | 77.8M | Perf Week | -5.72% |
| Market Cap | 1.21B | Forward P/E | 5.94 | EPS next Y | 6.18% | Insider Trans | - | Shs Float | 66.5M | Perf Month | -10.82% |
| Enterprise Value | 2.98B | PEG | 0.7 | EPS next Q | 0.56 | Inst Own | 95.35% | Short Float | 10.31% | Perf Quarter | -11.48% |
| Income | -0.01B | P/S | 0.73 | EPS this Y | 10.17% | Inst Trans | -1.82% | Short Ratio | 8.03 | Perf Half Y | 69.03% |
| Sales | 1.65B | P/B | 1.16 | EPS next 5Y | 8.53% | ROA | -0.2% | Short Interest | 6.86M | Perf YTD | 24.8% |
| Book/sh | 13.41 | P/C | 4.4 | EPS past 3/5Y | - | ROE | -0.7% | 52W High | -24.35% ($20.49) | Perf Year | 0.19% |
| Cash/sh | 3.52 | P/FCF | 46.72 | Sales past 3/5Y | 1.63% 3.57% | ROIC | -0.24% | 52W Low | 78.16% ($8.70) | Perf 3Y | -60.74% |
| Dividend Est. | - | EV/EBITDA | 9.04 | EPS Y/Y TTM | 98.56% | Gross Margin | 55.25% | Volatility(W/M) | 3.81% 3.62% | Perf 5Y | -77.93% |
| Dividend TTM | - | EV/Sales | 1.81 | Sales Y/Y TTM | 1.6% | Oper. Margin | 10.71% | ATR (14) | 0.72 | Perf 10Y | -63.13% |
| Dividend Ex-Date | - | Quick Ratio | 2.11 | EPS Q/Q | 100.91% | Profit Margin | -0.44% | RSI (14) | 32.85 | Recom | 2.75 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.6 | Sales Q/Q | 0.76% | SMA20 | -7.54% ($16.76) | Beta | 1.22 | Target Price | $19.56 |
| Payout | - | Debt/Eq | 1.96 | Earnings | 2026/7/29 | SMA50 | -12.01% ($17.62) | Rel Volume | 0.93 | Prev Close | $15.54 |
| Employees | 4427 | LT Debt/Eq | 1.91 | EPS/Sales Surpr. | 16.55% 0.29% | SMA200 | 11.72% ($13.87) | Avg Volume(3M) | 0.85M | Price | $15.5 |
| IPO | 1995/8/16 | Option/Short | Yes/Yes | Trades | 7766 | Volume | 792,026 | Change | -0.26% |
Company
IART is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧠 Integra LifeSciences (IART) is a U.S. medical device company whose core focus lies in neurosurgical technologies and regenerative medicine-based tissue repair. Its business is organized into two segments covering neurosurgical specialties—such as instruments for brain surgery, intracranial pressure monitoring, and dural repair grafts—and complex wound care along with peripheral nerve repair. The company is regarded as a niche leader with a sharp focus on specialty surgical areas.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
IART has weak earning power
10.71% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.2% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -60.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 95.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
HTEC 0.01%
XHE 0.01%
BTR 0.01%
FFLS 0.01%
NIXT 0.01%It ranks #4 in the industry
Based on market cap of $1B.
IART $1B PER -
ABT $176B PER 33.0
MDT $116B PER 22.4
SYK $106B PER 28.6
FAQ
What kind of company is IART?
IART belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of IART?
The market cap of IART is approximately $1.2B, ranking 2,493 within its sector.
What is the 52-week high and low for IART?
IART has recorded a 52-week high of $20.49 and a low of $8.70.
